If you have been reading about glucagon receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
Classical EDS is characterized by extremely elastic skin that is fragile and bruises easily, and hypermobility of the joints. Molluscoid pseudotumors (calcified hematomas that occur over pressure points) and spheroids (cysts that contain fat occurring over forearms and shins) are also often seen. A side complication of the hyperelasticity presented in many EDS cases makes wound closure on its own more difficult. Sometimes, motor development is delayed and hypotonia occurs. The variation causing this type of EDS is in the genes COL5A2, COL5A1, and less frequently COL1A1. It involves the skin more than hEDS. In classical EDS, large variation in symptom presentation is seen. Because of this variance, EDS has often been underdiagnosed. Without genetic testing, healthcare professionals may be able to provide a provisional diagnosis based on careful examination of the mouth, skin, and bones, as well as by neurological assessment. A good way to begin the diagnostic process is by reviewing a person's family history. EDS is an autosomal dominant condition, so it is often inherited from parents. Genetic testing remains the most reliable way to diagnose EDS. No cure for type 1 EDS has been found, but a course of non-weight-bearing exercise can help with muscular tension, which can help correct some EDS symptoms. Anti-inflammatory drugs and lifestyle changes can help with joint pain. Lifestyle choices should also be made with children who have EDS to try to prevent wounds to the skin. Protective garments can help with this.
=== Screenwriter === Culp wrote scripts for seven I Spy episodes, one of which he also directed. He later wrote and directed two episodes of The Greatest American Hero, including the series finale. Culp also wrote scripts for other television series, including Trackdown, a two-part episode from The Rifleman, and Cain's Hundred.
=== Hepatotoxicity === In large clinical trials, imipenem was associated with transient and asymptomatic elevations in serum aminotransferase levels in about 6% of patients given the drug for five to 14 days. More serious hepatic injury from imipenem/cilastatin is rare, but jaundice and liver test abnormalities have been reported in 0.1% of patients in prospective trials of the agent. Several instances of cholestatic jaundice arising during or shortly after therapy have been reported with imipenem-cilastatin and other carbapenems. The latency to onset has been within one to three weeks, and the pattern of enzyme elevations is usually cholestatic. Immunoallergic features can occur, but autoantibodies are rare. The course is usually self-limiting, but at least one case of vanishing bile duct syndrome related to the carbapenems has been reported. Imipenem and other carbapenems have not been linked to cases of acute liver failure.
== Criticism == Since the method measures only the amount that is retained in the body critics have pointed out what they perceive as a weakness of the biological value methodology. Critics have pointed to research that indicates that because whey protein isolate is digested so quickly it may in fact enter the bloodstream and be converted into carbohydrates through a process called gluconeogenesis much more rapidly than was previously thought possible, so while amino acid concentrations increased with whey it was discovered that oxidation rates also increased and a steady-state metabolism, a process where there is no change in overall protein balance, is created. They claim that when the human body consumes whey protein it is absorbed so rapidly that most of it is sent to the liver for oxidation. Hence they believe the reason so much is retained is that it is used for energy production, not protein synthesis. This would bring into question whether the method defines which proteins are more biologically utilizable. A further critique published in the Journal of Sports Science and Medicine states that the BV of a protein does not take into consideration several key factors that influence the digestion and interaction of protein with other foods before absorption, and that it only measures a protein's maximal potential quality and not its estimate at requirement levels.
The oxides B2O3, SiO2, GeO2, As2O3, and Sb2O3 readily form glasses. TeO2 forms a glass but this requires a "heroic quench rate" or the addition of an impurity; otherwise the crystalline form results. These compounds are used in chemical, domestic, and industrial glassware and optics. Boron trioxide is used as a glass fibre additive, and is also a component of borosilicate glass, widely used for laboratory glassware and domestic ovenware for its low thermal expansion. Most ordinary glassware is made from silicon dioxide. Germanium dioxide is used as a glass fibre additive, as well as in infrared optical systems. Arsenic trioxide is used in the glass industry as a decolourizing and fining agent (for the removal of bubbles), as is antimony trioxide. Tellurium dioxide finds application in laser and nonlinear optics. Amorphous metallic glasses are generally most easily prepared if one of the components is a metalloid or "near metalloid" such as boron, carbon, silicon, phosphorus or germanium. Aside from thin films deposited at very low temperatures, the first known metallic glass was an alloy of composition Au75Si25 reported in 1960. A metallic glass having a strength and toughness not previously seen, of composition Pd82.5P6Si9.5Ge2, was reported in 2011. Phosphorus, selenium, and lead, which are less often recognised as metalloids, are also used in glasses. Phosphate glass has a substrate of phosphorus pentoxide (P2O5), rather than the silica (SiO2) of conventional silicate glasses. It is used, for example, to make sodium lamps.
Sources: en.wikipedia.org
=== Luteal phase === Immediately after the LH surge and subsequent ovulation, estradiol concentrations drop and the corpus luteum develops. Towards the end of luteal phase, GnSAF production in the small antral follicles increases steadily. FSH does not stimulate GnSAF production in the corpus luteum, so GnSAF bioactivity is low after ovulation, until the intercycle rise in FSH occurs.
THIQ is a drug used in scientific research, which is the first non-peptide agonist developed that is selective for the melanocortin receptor subtype MC4. In animal studies, THIQ stimulated sexual activity in rats, but with little effect on appetite or inflammation. This supports possible application of MC4 selective agonists for the treatment of sexual dysfunction in humans, although THIQ itself has poor oral bioavailability and a short duration of action so improved analogues will need to be developed.
Cold-seep communities in the western Atlantic Ocean have also been described from a few dives on mud volcanoes and diapirs between 1,000 and 5,000 m (3,300–16,400 ft) depth in the Barbados accretionary prism area and from the Blake Ridge diapir off North Carolina. More recently, seep communities have been discovered in the eastern Atlantic, on a giant pockmark cluster in the Gulf of Guinea near the Congo deep channel, and also on other pockmarks of the Congo margin, Gabon margin and Nigeria margin and in the Gulf of Cádiz. The occurrence of chemosymbiotic biota in the extensive mud volcano fields of the Gulf of Cádiz was first reported in 2003. The chemosymbiotic bivalves collected from the mud volcanoes of the Gulf of Cadiz were reviewed in 2011. Cold seeps are also known from the Northern Atlantic Ocean, even ranging into the Arctic Ocean, off Canada and Norway. Extensive faunal sampling has been conducted from 400 and 3,300 m (1,300–10,800 ft) in the Atlantic Equatorial Belt from the Gulf of Mexico to the Gulf of Guinea including the Barbados accretionary prism, the Blake Ridge diapir, and in the Eastern Atlantic from the Congo and Gabon margins and the recently explored Nigeria margin during Census of Marine Life ChEss project. Of the 72 taxa identified at the species level, a total of 9 species or species complexes are identified as amphi-Atlantic. The Atlantic Equatorial Belt seep megafauna community structure is influenced primarily by depth rather than by geographic distance.
Consequently, independent homeowners inhibited the construction of New Deal sponsored public housing by using civic disorder and rioting as political tools to consolidate homeowner rejection of black occupancy in middle-class neighborhoods. Consequently, the political dominance white homeowners assumed in Detroit's housing disputes encouraged the Detroit Housing Commission (DHC) to establish racist policies, such as the continuation of racial segregation within Detroit's housing market, allowing the DHC to avoid the racial bloodshed of public housing construction. Additionally, New Deal policy promoted the formation of private-public partnerships to manage the allocation of federal funds within local municipalities. These private-public partnerships established residential segregation through a tactic called redlining, which restricted the movement of black Detroiters into middle-class neighborhoods. In particular, the Federal Housing Administration (FHA) and the Home Owners Loan Corporation (HOLC) effectively marked the racial boundaries of Detroit to determine the actuarial soundness of urban neighborhoods. Therefore, redlining governed the dispersal of federal loans and subsidies on the basis of the racial composition of a neighborhood. Local real estate brokers and lenders refused to allocate federal funds to predominantly black communities such as Paradise Valley along with neighborhoods that had only a handful of black residents as these areas were all categorized as unfit and hazardous investments for mortgages.
Sources: en.wikipedia.org
=== Hindi === Hindi has a finite list of compound words which are based on established grammatical rules of the language. The word commonly cited as the longest in Hindi is लौहपथगामिनीसूचकदर्शकहरितताम्रलौहपट्टिका (lauhapathagāminīsūcakadarśakaharitatāmralauhapaṭṭikā), which consists of 24 consonants and 10 vowel diacritics, making up a total of 34 characters. The word literally means "a green railway warning signboard made of copper-iron". Its plural would be लौहपथगामिनीसूचकदर्शकहरितताम्रलौहपट्टिकाएँ (lauhapathagāminīsūcakadarśakaharitatāmralauhapaṭṭikāẽ), which has an additional vowel and a diacritic. It is a neologism and not in common use. However this word is a direct loan word or borrowing from Sanskrit rather than a Hindi word. A much smaller word borrowed from Sanskrit which is in common use and is also often cited as the longest word is किंकर्तव्यविमूढ़ (kiṁkartavyavimūṛha). It consists of 8 consonants and 5 vowel diacritics, making up a total of 13 characters. The word literally means "confused about what to do", meaning to be bewildered or flabbergasted.
== History == It was published in 1950 by Blakiston. Creator and editor Tinsley Harrison's quotation appeared on the first edition of this book in 1950: No greater opportunity or obligation can fall the lot of a human being than to be a physician. In the care of suffering he needs technical skill, scientific knowledge and human understanding. He who uses these with courage, humility and wisdom will provide a unique service to his fellow man and will build an enduring edifice of character within himself. The physician should ask of his destiny no more than this and he should be content with no less. Blakiston was acquired by McGraw-Hill in 1954. The 17th edition of the textbook is dedicated to George W. Thorn, who was editor of the first seven editions of the book and editor in chief of the eighth edition. He died in 2004. The 18th edition of the book (ISBN 978-0071748896) was edited by Anthony Fauci, Dennis Kasper, Stephen Hauser, J. Larry Jameson and Joseph Loscalzo. New chapters added include "Systems Biology in Health and Disease," "The Human Microbiome," "The Biology of Aging," and "Neuropsychiatric Illnesses in War Veterans." The 19th edition of the book was edited by Dennis Kasper, Anthony Fauci, Stephen Hauser, Dan Longo, J. Larry Jameson and Joseph Loscalzo. AL.com in December 2014 wrote that it was still "a best-selling internal medicine text in the United States and around the world," and that it had been reprinted 16 times and translated into 14 languages. The 20th edition of the book, edited by Dennis Kasper, Anthony Fauci, Stephen Hauser, Dan Longo, J.
Enantiomers may not be isolable if there is an accessible pathway for racemization (interconversion between enantiomorphs to yield a racemic mixture) at a given temperature and timescale. For example, amines with three distinct substituents are chiral, but with few exceptions (e.g. substituted N-chloroaziridines), they rapidly undergo "umbrella inversion" at room temperature, leading to racemization. If the racemization is fast enough, the molecule can often be treated as an achiral, averaged structure.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.